^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TEAD1 inhibitor

    Related drugs:
    1m
    Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=67, Terminated, Ikena Oncology | N=198 --> 67 | Trial completion date: Jun 2025 --> Sep 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Aug 2024; Sponsor strategic reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    YAP1 (Yes associated protein 1) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • CAMTA1 (Calmodulin Binding Transcription Activator 1) • TAFAZZIN (Tafazzin)
    |
    TFE3 fusion
    |
    Tagrisso (osimertinib) • IK-930
    6ms
    Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=198, Active, not recruiting, Ikena Oncology | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    YAP1 (Yes associated protein 1) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • CAMTA1 (Calmodulin Binding Transcription Activator 1) • TAFAZZIN (Tafazzin)
    |
    Tagrisso (osimertinib) • IK-930
    8ms
    Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=198, Recruiting, Ikena Oncology | Trial completion date: Oct 2024 --> Jun 2025 | Trial primary completion date: Oct 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    YAP1 (Yes associated protein 1) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • CAMTA1 (Calmodulin Binding Transcription Activator 1) • TAFAZZIN (Tafazzin)
    |
    TFE3 fusion
    |
    Tagrisso (osimertinib) • IK-930
    almost2years
    A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy (AACR 2023)
    (iv) favorable ADME profile in rodents, dogs and NHPs, as well as a favorable safety profile. In sum, SPR1 presents monotherapy opportunities in ultra-responder populations based on internal bioinformatic insights, while broader potential exists as an adjuvant for precision oncology targeted therapies, particularly within the MAPK pathway and its upstream activators.
    Clinical
    |
    YAP1 (Yes associated protein 1) • WWTR1 (WW Domain Containing Transcription Regulator 1) • TEAD1 (TEA Domain Transcription Factor 1)
    |
    SPR1-0117